Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resuscitative Endovascular Balloon Occlusion of the Aorta in Non-traumatic Out of Hospital Cardiac Arrest (REBOARREST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04596514
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : June 18, 2021
Sponsor:
Collaborator:
Norwegian Air Ambulance Foundation
Information provided by (Responsible Party):
St. Olavs Hospital

Brief Summary:

The primary aim of this trial is to assess the efficacy of resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct treatment to advanced cardiovascular life support (ACLS) in patients with out-of-hospital cardiac arrest.

Out of hospital cardiac arrest (OHCA) carries a high mortality rate. The treatment of out-of-hospital cardiac arrest is ACLS as stated in the guidelines from the Norwegian Resuscitation Council and the European Resuscitation Guidelines.

Recently, REBOA has been proposed as an adjunct treatment in management of non-traumatic cardiac arrest patients, because thoracic aortic occlusion provides a redistribution of the cardiac output to organs proximal to the occlusion. Preclinical studies demonstrate that REBOA during CPR provide both increased coronary artery blood flow and perfusion pressure and increased rates of return of spontaneous circulation (ROSC).

This is the first prospective trial in the world to assess the efficacy of REBOA in non-traumatic cardiac arrest. The intervention is shown feasible in the pre-hospital setting. If this trial provides a signal of benefit in patients, this study could initiate further clinical research which could change current resuscitation practice world-wide.


Condition or disease Intervention/treatment Phase
Cardiac Arrest Procedure: REBOA Procedure: usual procedure according to guidelines Not Applicable

Detailed Description:

This is a prospective, randomised, parallel group, multi-centre, phase II clinical trial.

Patients are randomised in a 1:1 ratio to be included to the control group or the intervention group. The control group receives ACLS according to national guidelines, while the intervention group receives ACLS according to national guidelines and the REBOA procedure as an adjunct treatment.

The REBOA procedure is performed by a team consisting of a physician (anesteshiologist) and a paramedic, working at a helicopter emergency medical service (HEMS) base. All operators will be properly educated and tested before they can include patients.

If the patients in the intervention group achieves ROSC, the balloon will be deflated and post-ROSC treatment will be continued as per routine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Blinded from the statisticians who carry out analyses
Primary Purpose: Treatment
Official Title: A Randomised Trial on Resuscitative Endovascular Balloon Occlusion of the Aorta in Non-traumatic Out of Hospital Cardiac Arrest
Actual Study Start Date : June 7, 2021
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention group - REBOA
Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
Procedure: REBOA
Resuscitative endovascular balloon occlusion of the aorta (REBOA)

Procedure: usual procedure according to guidelines
Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines

Active Comparator: Control group - ACLS
Advanced cardiovascular life support as described in the guidelines
Procedure: usual procedure according to guidelines
Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines




Primary Outcome Measures :
  1. Proportion of patients that achieve return of spontaneous circulation (ROSC) with a duration of at least 20 minutes. [ Time Frame: 60 minutes ]
    Sustained ROSC means return of spontaneous circulation with a duration of at least 20 minutes.


Secondary Outcome Measures :
  1. The proportion of patients surviving to 30 days with good neurologic status, defined as a modified Rankin scale (mRS) score 0-3. [ Time Frame: 30 days ]
    The mRs are dichotomised into good (score 0-3) and poor (score 4-6) neurological state.

  2. Difference in end-tidal CO2 (EtCO2) measurements between control group and intervention group after aortic occlusion. [ Time Frame: 15 minutes ]
    In the control group, EtCO2 is measured after airway management is completed. In the intervention group, EtCO2 is measured after airway management is completed, before balloon inflation and 30, 60 and 90 seconds after balloon inflation.

  3. Change in blood pressures after aortic occlusion [ Time Frame: 15 minutes ]
    In the intervention group, intra-aortic blood pressure measurements from the REBOA catheter are recorded. This applies only to the catheters with CE/FDA approval for invasive blood pressure measurements and will therefore be assessed in a sub-group of the participants. Continuous registration of invasive blood pressure will start before aortic occlusion.

  4. Difference in left ventricular ejection fraction (LVEF) measured by echocardiography [ Time Frame: 1-2 weeks ]
    Echocardiography after admission, after a few days-up to one week and at discharge will be assessed - both from the control and intervention group.


Other Outcome Measures:
  1. Exploratory outcome - All-cause mortality one year after randomization [ Time Frame: One year ]
    Difference in all-cause mortality between the intervention and control group after one year.

  2. Exploratory outcome - Difference in renal function between intervention and control group [ Time Frame: 30 days ]
    Values of serum creatinine (umol/L) and urine output (ml/kg/h) will be combined to classify renal function according to the Acute Kidney Injury Network (AKIN) classification, into stage 1-3.

  3. Exploratory outcome - difference in the need for renal replacement therapy between intervention and control group [ Time Frame: 30 days ]
    Number of days renal replacement therapy is needed

  4. Exploratory outcome - difference in the liver function (albumine) between intervention and control group [ Time Frame: 30 days ]
    Value of albumine (mg/L)

  5. Exploratory outcome - difference in the liver function (ASAT/ALAT) between intervention and control group [ Time Frame: 30 days ]
    Value of ASAT and ALAT (U/L)

  6. Exploratory outcome - Incidents of all adverse events [ Time Frame: 30 days ]
    assessment of all adverse events, both suspected and unsuspected, in both intervention and control group



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • out-of-hospital cardiac arrest
  • non-traumatic cardiac arrest
  • less than 10 minutes from debut of arrest to start of basic or advanced cardiac life support
  • advanced cardiac life support is established and can be continued

Exclusion Criteria:

  • traumatic cardiac arrest, including strangulation, electrocution and patients rescued from avalanches
  • accidental hypothermia with temperature < 32 0C
  • suspected cerebral hemorrhage as etiology of the arrest
  • suspected non-traumatic hemorrhage as etiology of the arrest
  • pregnancy, obvious or suspected
  • patient included to the study site's E-CPR protocol
  • other factors as decided by the treatment team (environmental factors, safety factors and others)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04596514


Contacts
Layout table for location contacts
Contact: Andreas Jørstad Krüger, md phd +47 908 62 586 Andreas.kruger@ntnu.no
Contact: Jostein Rødseth Brede, md +47 994 45 914 Jostein.brede@norskluftambulanse.no

Locations
Layout table for location information
Norway
St Olavs Hospital Recruiting
Trondheim, Norway, 7030
Contact: Jostein R Brede, md phd       jostein.brede@norskluftambulanse.no   
Sponsors and Collaborators
St. Olavs Hospital
Norwegian Air Ambulance Foundation
Investigators
Layout table for investigator information
Study Director: Rune Wiseth, md phd St Olav's Hospital
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: St. Olavs Hospital
ClinicalTrials.gov Identifier: NCT04596514    
Other Study ID Numbers: U1111-1253-0322
U1111-1253-0322 ( Registry Identifier: WHO Universal Trial Number UTN )
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: June 18, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The full study protocol, statistical analysis plan, information letter for consent and other trial documents will be published open access. The clinical study report and statistical analysis report will also be made openly available but may be altered to hide information that may lead to identification of individual study participants. These documents will be shared at HUNT Cloud.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Study protocol and ICF will be available before study start. SAP will be available before first interim analysis.
Access Criteria:

Individual level data will be made available to sponsor institutions on the REBOARREST data space in HUNT Cloud. Access will be controlled by a data processor agreement between the partner and funder. Pseudonymous individual level data collected during the trial, will be made available on request to researchers from other scientific institutions by approval of the project management to ensure that usage is compliant with privacy and consent requirements as well as conditions for attribution and usage.

Data sharing with editors or peer-reviewers of scientific journals, conferences or the like will not require additional consent or data access agreement with sponsor, as such data will not be shared onward or used beyond reviewing this trial.

After data sharing, the sponsor must be acknowledged in any publication resulting from the shared data. For closer collaboration attribution based on the Vancouver Convention will apply.

URL: http://www.reboarrest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by St. Olavs Hospital:
Reboa procedure
aortic occlusion
resuscitation
pre-hospital emergency care
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Out-of-Hospital Cardiac Arrest
Heart Diseases
Cardiovascular Diseases